Media Articles Related to Zebeta (Bisoprolol)
New Hypertension After 80 Linked to Lower Dementia Risk
Source: Medscape NeurologyHeadlines [2014.07.14]
New results from the 90+ Study show new hypertension after 80 years of age not only doesn't increase dementia risk but is actually associated with reduced risk.
Medscape Medical News
Treatment-resistant hypertension requires proper diagnosis
Source: Hypertension News From Medical News Today [2014.07.09]
High blood pressure - also known as hypertension - is widespread, but treatment often fails. One in five people with hypertension does not respond to therapy.
Hypertension, antihypertension medication and risk of psoriasis
Source: Hypertension News From Medical News Today [2014.07.04]
Women with long-term high blood pressure (hypertension) appear to be at an increased risk for the skin condition psoriasis, and long-term use of beta (β)-blocker medication to treat hypertension...
Risk of hypertension increased in pregnancies resulting from egg donation
Source: Fertility News From Medical News Today [2014.07.02]
With an ever-ageing female patient population, egg donation is an increasingly common treatment in infertility.
Genetic study suggests causal link between vitamin D deficiency and hypertension
Source: Hypertension News From Medical News Today [2014.06.27]
New genetic research provides compelling evidence that low levels of vitamin D have a causal role in the development of high blood pressure (hypertension).
Published Studies Related to Zebeta (Bisoprolol)
Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. [2011.07]
CONCLUSION: The order of drug administration plays an important role in whether CHF patients reach target doses of bisoprolol and enalapril. For both study drugs, the dose level reached was associated with baseline characteristics and adverse events. In CHF patients not treated with an ACE-I or a beta-blocker, the duration of monotherapy with either type of drug should be shorter than 6 months.
Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. [2011.06]
CONCLUSION: Overall tolerability to target doses was comparable. The pattern of intolerance, however, was different: bradycardia occurred more often in the bisoprolol group, whereas pulmonary adverse events occurred more often in the carvedilol group. This study is registered with controlled-trials.com, number ISRCTN34827306.
Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II). [2011.02]
CONCLUSIONS: The FSQ performed well in this study, provided additional information to the MLwHF questionnaire and allowed interesting comparisons with other chronic medical conditions. The FSQ may be a useful general QoL instrument for studies in CHF.
Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. [2011.01.15]
Atrial fibrillation (AF) occurs frequently soon after coronary artery bypass grafting (CABG) and often results in increased mortality and morbidity, particularly in patients with heart failure. New-onset AF is also a common event in the early period after discharge from a cardiac surgery clinic... In conclusion, bisoprolol is more effective than carvedilol in decreasing the incidence of postdischarge AF after CABG in patients with decreased left ventricular function.
The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure. [2010.09.24]
BACKGROUND: In CIBIS III, initiating chronic heart failure (CHF) treatment with bisoprolol (target dose 10 mg q.d.) followed by combination therapy with enalapril (target dose 10 mg b.i.d.), compared to the opposite order, showed similar effects on survival and hospitalization. By echocardiography, we evaluated the effects of these treatment strategies on cardiac structure and function... CONCLUSION: During both monotherapy and combined therapy, bisoprolol-first and enalapril-first similarly reversed cardiac remodelling and improved LVEF. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
Clinical Trials Related to Zebeta (Bisoprolol)
Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Patients With Suboptimal Blood Pressure Control (GIANT Study) [Recruiting]
This is a 24-week, prospective, multicenter, open-label, single arm study to assess the
effect of bisoprolol on glycemic level in Type II diabetes mellitus (DM) controlled subjects
with hypertension. The hypothesis of study is that there is no change in glycemic level and
lipid metabolism as determined by HbA1C using bisoprolol in Type II DM subjects with
suboptimal blood pressure (BP) control.
A 12-week, Multicentric Study to Evaluate the Safety and Efficacy of Bisoprolol in Diabetic and Hypertensive Filipinos [Recruiting]
The aim of this 12-week, multicenter, interventional, prospective, open-label and
uncontrolled study is to evaluate the safety and efficacy of 5 mg/day and 10 mg/day
bisoprolol in hypertensive and diabetic Filipino subjects as monotherapy or as an add-on
An Active-controlled, Clinical Trial to Assess Central Haemodynamic Effects of Bisoprolol in Hypertensive Patients [Recruiting]
Antihypertensive drugs aim to reduce blood pressure (BP) either through decrease of the
total peripheral resistance through vasodilatation at the level of arterioles
(microcirculation) or by decreasing the cardiac output through reduction of the stroke
volume or heart rate or both. On the other hand, all antihypertensives drugs might
potentially decrease arterial stiffness passively with the reduction of the distending
pressure or with the re synchronisation of the reflected pressure wave. With theses
potential mechanisms, it is also expected that these drugs might exert a favourable effect
on pulse pressure amplification between central and peripheral arteries.
However, there is a solid evidence that the widely applied antihypertensive drugs has
differential effect on brachial and central BP. Several reports in the past has confirmed
the potential hypothesis that beta blockers decrease central BP less than the observed
reduction at the level of the brachial artery. It has been hypothesised that deceleration of
heart rate and the re synchronizing the reflected pressure wave earlier in the systolic
phase seems to be the leading cause of non-favourable effect of beta blockers on central BP,
these effects might be partially counterbalanced in beta blockers with high beta-1
selectivity resulting in less peripheral vasoconstriction properties.
The primary and secondary hypothesis for this prospective, multi-center, randomised, open
label, active-controlled clinical trial are as follows:
- Treatment with bisoprolol for 12 weeks significantly reduces the aortic pulse pressure
as compared to atenolol group
- Treatment with bisoprolol for 12 weeks significantly reduces the aortic BP as compared
to atenolol group
- The efficacy of bisoprolol in reducing peripheral BP is comparable with that of
A Prospective, Open-labeled Trial in Patients With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea [Recruiting]
This is a prospective, open-labeled, multicentric trial to evaluate the effect of bisoprolol
(between low-dose and high dose) on surrogate markers of heart failure in Korea.
A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension [Recruiting]
This is a phase IV, prospective, multi-centric and randomized controlled study to compare
the effects of bisoprolol and atenolol on resting heart rate (RHR) and sympathetic nervous
system's (SNS) activity in subjects with essential hypertension. A total of 192 subjects are
planned to be enrolled in various centers in China.